Barclays PLC Inhibrx, Inc. Transaction History

Barclays PLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$32.76 - $39.56 $6.34 Million - $7.65 Million	193,438 Added 217.68%	282,303 $9.87 Million
Q4 2023 Feb 15, 2024	BUY	$14.5 - $38.0 $372,476 - $976,144	25,688 Added 40.66%	88,865 $3.11 Million
Q3 2023 Nov 07, 2023	SELL	$15.75 - $26.31 $84,372 - $140,942	-5,357 Reduced 7.82%	63,177 $1.15 Million
Q2 2023 Aug 03, 2023	BUY	$16.96 - $27.82 $65,686 - $107,746	3,873 Added 5.99%	68,534 $1.76 Million
Q1 2023 May 04, 2023	SELL	$18.45 - $27.14 $773,829 - $1.14 Million	-41,942 Reduced 39.34%	64,661 $1.19 Million
Q4 2022 Feb 13, 2023	BUY	$20.18 - $33.33 $394,014 - $650,768	19,525 Added 22.42%	106,603 $2.56 Million
Q3 2022 Nov 03, 2022	BUY	$11.58 - $24.73 $972,499 - $2.08 Million	83,981 Added 2711.69%	87,078 $1.52 Million
Q2 2022 Aug 12, 2022	SELL	$8.52 - $25.26 $12,618 - $37,410	-1,481 Reduced 32.35%	3,097 $38,000
Q1 2022 May 16, 2022	BUY	$19.89 - $43.18 $91,056 - $197,678	4,578 New	4,578 $102,000

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $570M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.